- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
Michael Wang, MD | Authors
Michael Wang, MD, Reviews Results of Ibrutinib Plus Bendamustine and Rituximab in Elderly Patients With First-Line MCL
October 14, 2022
Michael Wang, MD, spoke about key data from the phase 3 SHINE trial which analyzed the use of first-line ibrutinib plus bendamustine and rituximab in older patients with mantle cell lymphoma.
Overview and Management of Cardiac and Pulmonary Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
December 01, 2013
This article presents an overview of the cardiac and pulmonary safety profile of single-agent carfilzomib therapy in patients with relapsed and/or refractory multiple myeloma from an analysis of four phase II clinical studies, and provides practical recommendations for the management of patients at risk for cardiac events and pulmonary complication.
Comparative Mechanisms of Action of Proteasome Inhibitors
November 07, 2011
The proteasome is an important therapeutic target in the treatment of a small but increasing number of diseases- most notably, B cell malignancies. Multiple myeloma (MM) is one of the first diseases for which proteasome inhibitors (PIs) have been validated and in which they have found widespread use.